The Iressa Pan‐Asia Study (IPASS)4 initiated the era of targeted therapy for lung cancer, and established the role of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) in EGFR mutant–positive NSCLC patients, thus opening a new direction for lung cancer research. The gene discussed is EGFR; the disease is lung carcinoma.